SCHEMBL4510378

SCHEMBL4510378

O=C1C(Cc2ccc(NS(=O)(=O)c3ccc(F)cc3)cc2Cl)CCN1C1C2CC3CC1CC(O)(C3)C2

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.51
HSD17B3 P37058 1/20 0.41
HSD17B2 P37059 1/20 0.41
POLB P06746 1/20 0.37
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
HTR6 P50406 2/20 0.36
EPHX2 P34913 1/20 0.36
KMT2A Q03164 2/20 0.35
RORC P51449 2/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
TP53 P04637 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4501696 0.92 HSD11B1 (0.49) HSD11B1HTR6EPHX2MAPT
SCHEMBL4516085 0.88 HSD11B1 (0.55) HSD11B1HPGDEPHX2
SCHEMBL4510336 0.87 HSD11B1 (0.55) HSD11B1EPHX2
SCHEMBL4516953 0.86 HSD11B1 (0.54) HSD11B1EPHX2
SCHEMBL4513385 0.85 HSD11B1 (0.63) HSD11B1ALDH1A1HPGDKMT2ASMN1; SMN2
SCHEMBL5548875 0.84 HSD11B1 (0.63) HSD11B1KMT2A
SCHEMBL4524294 0.84 HSD11B1 (0.59) HSD11B1
SCHEMBL4503344 0.83 HSD11B1 (0.47) HSD11B1POLBALDH1A1HPGDHTR6
SCHEMBL13675599 0.82 HSD11B1 (0.56) HSD11B1
SCHEMBL4501204 0.82 HSD11B1 (0.56) HSD11B1ALDH1A1EPHX2RORCKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD17B3 10/4885HSD17B2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.